🧪
hypothesis

TREM2 Microglial Activation Rescues Amyloid Clearance in AD

Hypothesis

TREM2 Microglial Activation Rescues Amyloid Clearance in AD

TREM2 agonistic antibodies restore microglial phagocytosis and plaque compaction in Alzheimer's disease, particularly for R47H variant carriers with ~3-fold increased AD risk.
🧬 TREM2🩺 neurodegeneration🎯 Composite 68%💱 $0.67▼18.8%debated
EvidencePending (0%)📖 0 cit🗣 2 debates✓ 3 support✗ 3 oppose
✓ All Quality Gates Passed
Mechanistic 0.75 (15%) Evidence 0.82 (15%) Novelty 0.60 (12%) Feasibility 0.62 (12%) Impact 0.85 (12%) Druggability 0.68 (10%) Safety 0.65 (8%) Competition 0.75 (6%) Data Avail. 0.72 (5%) Reproducible 0.65 (5%) KG Connect 0.53 (8%) 0.682 composite
☰ Compare⚔️ Duel⚛️ Collide
📄 Export LaTeX
arXiv PreprintNeurIPSNature MethodsPLOS ONE
📖 Export BibTeXinteract with this hypothesis
Composite68% · Elo1533(2 matches) · Arena1W·1L·0D

🧪 Overview

TREM2 agonistic antibodies restore microglial phagocytosis and plaque compaction in Alzheimer's disease, particularly for R47H variant carriers with ~3-fold increased AD risk. Multiple agonistic antibodies (AL002c, 4D9) are in development targeting the SYK/PLCγ2/CARD9 cascade. Critical uncertainties include biphasic dose-response pharmacology, appropriate mouse model design (conditional knockout rather than constitutive knockout), and the temporal window for therapeutic intervention given biphasic CSF sTREM2 patterns in AD patients.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["TREM2 Activation<br/>Microglial Receptor"]
    B["Amyloid Plaque<br/>Phagocytosis"]
    C["Homeostatic to DAM<br/>Microglia Transition"]
    D["Lysosomal<br/>Biomolecule Processing"]
    E["Neuroinflammatory<br/>Resolution"]
    F["Synaptic<br/>Protection"]
    G["Cognitive<br/>Preservation"]
    A --> B
    B --> C
    C --> D
    D --> E
    E --> F
    F --> G
    style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
    style C fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
    style G fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7

⚖️ Evidence

⚖️ Evidence Matrix3 supports3 contradicts
Supports
TREM2 R47H variant increases AD risk ~3-fold
PMID:26043671
Supports
TREM2-deficient mice show altered microglial transcriptomics around plaques
PMID:27929084
Supports
Trem2 haploinsufficiency accelerates plaque pathology in 5xFAD mice
PMID:29080823
Contradicts
TREM2 loss paradoxically reduces plaque burden in some 5xFAD crosses
PMID:26069164
Contradicts
CSF sTREM2 shows biphasic temporal pattern in AD—elevated early, suppressed late
PMID:27187225
Contradicts
High TREM2 agonist concentrations cause receptor internalization and desensitization
PMID:29429981
📖 Linked Papers (4)Export BibTeX ↗
Synergistic potential of TREM2 agonists and exercise training in Alzheimer's disease.
Am J Physiol Endocrinol Metab (2026) · PubMed:41494649 ↗
1 figure
Figures
Figures
Figures available at source paper (no open-access XML found).
Interplay between CD33 and TREM2 in Alzheimer's Disease: Potential Mechanistic Insights into Microglial Function in Amyloid Pathology.
ACS chemical neuroscience (2026) · PubMed:41388352 ↗
No figures
Discovery and engineering of an anti-TREM2 antibody to promote amyloid plaque clearance by microglia in 5XFAD mice.
mAbs (2022) · PubMed:35921534 ↗
No figures
Microglial mTOR Activation Upregulates Trem2 and Enhances β-Amyloid Plaque Clearance in the
The Journal of neuroscience : the official journal of the Society for Neuroscience (2022) · PubMed:35672148 ↗
No figures

🏥 Translation

🧬 3D Protein Structure — TREM2

🧬 PDB 6YXY Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

🧠 GTEx v10 Brain ExpressionJSON

Median TPM across 13 brain regions for TREM2 from GTEx v10.

Spinal cord cervical c-148.4 Substantia nigra20.7 Hypothalamus10.9 Hippocampus9.8 Amygdala8.9 Caudate basal ganglia7.9 Putamen basal ganglia6.6 Nucleus accumbens basal ganglia6.2 Anterior cingulate cortex BA245.6 Frontal Cortex BA95.1 Cortex3.5 Cerebellar Hemisphere2.9 Cerebellum1.5median TPM (GTEx v10)

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for TREM2 →

No DepMap CRISPR Chronos data found for TREM2.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

🏆 Tournament

🏆 Arenas / Elo

Elo Rating
1533 ±247
Record
1W / 1L / 0D
2 matches
Full Lineage ➔

📊 Market Indicators

7d Trend
↘
Falling
7d Momentum
▼ 2.3%
Volatility
High
0.0944
Events (7d)
3
Price History
▼18.8%

💾 Resource Usage

No resource usage or linked notebooks recorded for this hypothesis yet.

🔮 Predictions

🔎 Predictions vs Observations2 predictions · 0 with recorded observations
PredictionPredictedObservedStatusConf
IF heterozygous R47H TREM2 variant carriers with early-stage Alzheimer's disease (MMSE 20-26) receive 12 months of subcutaneous TREM2 agonistic antibody (AL002c at 5mg/kg biweekly) THEN their CSF Aβ42Mean increase in CSF Aβ42/40 ratio of ≥15% from baseline in the treatment arm, with statistical significance (p<0.05) versus placebo.— no observation —pending0.45
IF aged 18-month 5xFAD mice with conditional TREM2 deletion (Trem2-flox/Cre-ERT2, not constitutive KO) receive intraperitoneal 4D9 antibody at 3mg/kg twice weekly for 8 weeks THEN microglial plaque coMean microglial plaque coverage increase of ≥40% in TREM2-agonist-treated conditional KO mice versus vehicle controls, with reduced plaque diameter and increase— no observation —pending0.52
🔮 Falsifiable Predictions (2)
pendingconf 52%
IF aged 18-month 5xFAD mice with conditional TREM2 deletion (Trem2-flox/Cre-ERT2, not constitutive KO) receive intraperitoneal 4D9 antibody at 3mg/kg twice weekly for 8 weeks THEN microglial plaque coverage (Iba1+ area colocalized with 6E10+ plaques) will increase by ≥40% compared to vehicle-treated
Predicted outcome: Mean microglial plaque coverage increase of ≥40% in TREM2-agonist-treated conditional KO mice versus vehicle controls, with reduced plaque diameter an
Falsification: Microglial plaque coverage shows no significant increase (<15%) or actual decrease in TREM2-agonist-treated conditional KO mice compared to vehicle, or no difference between conditional KO and WT mice
pendingconf 45%
IF heterozygous R47H TREM2 variant carriers with early-stage Alzheimer's disease (MMSE 20-26) receive 12 months of subcutaneous TREM2 agonistic antibody (AL002c at 5mg/kg biweekly) THEN their CSF Aβ42/40 ratio will increase by ≥15% from baseline (indicating reduced amyloid burden) compared to age-ma
Predicted outcome: Mean increase in CSF Aβ42/40 ratio of ≥15% from baseline in the treatment arm, with statistical significance (p<0.05) versus placebo.
Falsification: CSF Aβ42/40 ratio shows no significant change (difference <5%) or decreases in R47H carriers receiving TREM2 agonist compared to placebo after 12 months.
View on SciDEX ↗